Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17 –30 months

ConclusionApproximately 55% of treatment resistant or difficult to treat CM patients who trialled erenumab in our clinics reported a subjective benefit and were still on treatment after 17 –30 months.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research